BIO-Europe: Mendus is developing cancer immunotherapies that focus on dendritic cell biology - an AML program will have a data update at #ASH24

blonca9
Nov 5, 2024
1 min read

CEO Erik Manting describes the rationale for focusing on dendritic cell biology, and covers previous data the company has presented in AML with its whole cell based cancer vaccine.

Brought to you by

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

BIO-Europe: Mendus is developing cancer immunotherapies that focus on dendritic cell biology - an AML program will have a data update at #ASH24

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight